Effective December 1, 2026: Pharmacy and Biopharmacy Policies
Date: 11/20/26
Ambetter from Superior HealthPlan, Ambetter Health (Solutions), and Superior HealthPlan (Medicaid and CHIP) has added, updated, or retired certain pharmacy and biopharmacy policies to ensure medical necessity review criteria is current and appropriate for members and the scope of services provided. As a result, the following policies are effective on December 1, 2026, at 12:00 AM.
Changes in these policies reflect preauthorization requirement amendments that are less burdensome to insureds, physicians, or health care providers.
Policy | Applicable Products | New Policy Overview or Updated Policy Revisions |
Autologous Cutaneous Multicellular Units (SkinTE) (CP.PHAR.814) | Ambetter Health, Ambetter, and Medicaid (STAR, STAR Health, STAR Kids, STAR+PLUS), CHIP | Policy created pre-emptively |
Dersimelagon (MT-7117) (CP.PHAR.815) | Ambetter Health, Ambetter | Policy created pre-emptively |
Efzimfotase Alfa (ALXN1850) (CP.PHAR.816) | Ambetter Health, Ambetter, and Medicaid (STAR, STAR Health, STAR Kids, STAR+PLUS), CHIP | Policy created pre-emptively |
Psilocybin (COMP360) (CP.PHAR.817) | Ambetter Health, Ambetter | Policy created pre-emptively |
Sofosbuvir-Velpatasvir (Epclusa) (HIM.PA.SP1) | Ambetter Health, Ambetter | Per September SDC: removed criterion requiring life expectancy > 12 months with HCV treatment; for continued therapy, added criterion requiring use of authorized generic version of Epclusa. |
Sofosbuvir-Vepatasvir-Voxilaprevir (Vosevi) (HIM.PA.SP63) | Ambetter Health, Ambetter | Per September SDC: removed criterion requiring life expectancy > 12 months with HCV treatment. |
Nirsevimab (Beyfortus) (CP.PHAR.614) | Ambetter Health, Ambetter | Added criteria allowing use in the second RSV season for GA < 32 weeks, Down syndrome or other chromosomal differences per updated AAP recommendations. |
Levacetylleucine (Aqneursa) (CP.PHAR.682) | Ambetter Health, Ambetter | 4Q 2026 annual review: updated NPC diagnostic criterion to require confirmation by biallelic pathogenic variants in NPC1 or NPC2 gene per updated international consensus guidelines; references reviewed and updated. |
| Satralizumab-mwge (Enspryng) (CP.PHAR.463) | Ambetter Health, Ambetter, and Medicaid (STAR, STAR Health, STAR Kids, STAR+PLUS), CHIP | RT4: added newly approved indication for TED and new 180 mg/1.5 mL autoinjector strength. |
| Tucatinib (Tukysa) (CP.PHAR.497) | Ambetter Health/Ambetter | RT4: added new indication in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment. |
| Lurbinectedin (Zepzelca) (CP.PHAR.500) | Ambetter Health, Ambetter, and Medicaid (STAR, STAR Health, STAR Kids, STAR+PLUS), CHIP | RT4: updated FDA Approved Indication(s) section for withdrawal of SCLC monotherapy accelerated approval indication and added “off-label” parenthetical notation for the corresponding criteria per current NCCN support. |
| Dostarlimab-gxly (Jemperli) (CP.PHAR.540) | Ambetter Health/Ambetter | RT4: added newly approved indication of MSI-H/dMMR Stage II/III LARC; for primary advanced or recurrent EC, added “up to a total of 3 years” to dosing requirement in continued criteria per PI. |
| Denosumab (Prolia, Xgeva and biosimilars) (CP.PHAR.58) | Medicaid (STAR, STAR Health, STAR Kids, STAR+PLUS), CHIP | RT4: added new biosimilar Degevma to criteria; added Q5173 HCPCS code; updated Appendix E with revised language for Tennessee. |
| Pirtobrutinib (Jaypirca) (CP.PHAR.620) | Ambetter Health/Ambetter | RT4: added indication for previously untreated CLL/SLL with no known del(17p)/TP53 mutation per updated prescribing information and NCCN supported off-label uses; for CLL/SLL, added use in del(17p)/TP53 mutation for older patients with cardiac comorbidities, combination use with Venclexta and rituximab, and combination use with Venclexta and Gazvya per NCCN. |
| Brepocitnib (Lisraya) (CP.PHAR.793) | Ambetter Health/Ambetter | Drug is now FDA approved – criteria updated per FDA labeling: added “member does not have combination use with DMARDs, JAK inhibitors, or TYK2 inhibitors”; added required pre-treatment monitoring parameters, including active infections screening, lymphocyte count, neutrophil count, hemoglobin level; added HCPC code [J8499]; references reviewed and updated. |
| Zilurgisertib (Atebrioz) (CP.PHAR.796) | Ambetter Health/Ambetter | RT4: Drug is now FDA approved – criteria updated per FDA labeling: added medical genetics to list of provider specialty options; for initial approval criteria, added requirement for CAJIS score ≤ 23 prior to treatment with Atebrioz; for initial therapy, specified documentation of baseline HO volume; for initial and continued therapy sections, added requirement that Atebrioz is not prescribed concurrently with Pasatru; added Appendix E for CAJIS scoring; references reviewed and updated. |
| Mavacamten (Camzyos) (CP.PMN.272) | Ambetter Health/Ambetter | RT4: added extension for pediatric members weighing ≥ 30 kg, revised NYHA Class III to Class IV, and added new 1 mg capsule strength per updated Prescribing Information; added left ventricular thickness diagnostic requirements specific to pediatric members per practice guidelines; added quantity limit. |
To review all policies, please visit Superior’s Clinical, Payment & Pharmacy Policies webpage.
Prior to updates, pharmacy and biopharmacy clinical policies are reviewed and approved by the Pharmacy and Therapeutics (P&T) Committee.
For questions or additional information, please contact the Centene Pharmacy Services (CPS) at 1-866-768-7147.